BRIEF published on 10/24/2024 at 09:35, 2 years ago QUANTRO Therapeutics et IMP forment une alliance de recherche pour la découverte de médicaments Thérapie Contre Le Cancer Découverte De Médicaments Thérapeutique QUANTRO Collaboration IMP Facteur De Transcription
PRESS RELEASE published on 10/24/2024 at 09:30, 2 years ago QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery QUANTRO Therapeutics partners with IMP to advance transcriptomic drug discovery. Strategic collaboration to explore transcription factors' functions for cancer therapies QUANTRO Therapeutics Transcription Factors IMP Transcriptomic Drug Discovery Cancer Therapies
BRIEF published on 08/06/2024 at 10:05, 2 years 2 months ago QUANTRO Therapeutics obtient une subvention de recherche autrichienne clé pour faire progresser le développement de la plateforme Découverte De Médicament QUANTRO Thérapeutique Bourse FFG Plateforme Transcriptomique Multiplexage
BRIEF published on 08/06/2024 at 10:05, 2 years 2 months ago QUANTRO Therapeutics Secures Key Austrian Research Grant to Advance Platform Development Drug Discovery QUANTRO Therapeutics FFG Grant Transcriptomic Platform Multiplexing
PRESS RELEASE published on 08/06/2024 at 10:00, 2 years 2 months ago QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform QUANTRO Therapeutics secures Austrian research grant to accelerate cutting-edge platform development, enabling multiplex target screening in drug discovery Drug Discovery QUANTRO Therapeutics Austrian Research Grant Transcriptomic Discovery Platform Multiplexing Capabilities
BRIEF published on 06/04/2024 at 23:12, 2 years 4 months ago QUANTRO Therapeutics franchit une étape importante en collaboration avec Boehringer Ingelheim Boehringer Ingelheim QUANTRO Thérapeutique Traitements Contre Le Cancer Facteurs De Transcription Collaboration R&D
BRIEF published on 06/04/2024 at 23:12, 2 years 4 months ago QUANTRO Therapeutics Reaches Milestone in Collaboration with Boehringer Ingelheim Cancer Treatments R&D Collaboration Boehringer Ingelheim QUANTRO Therapeutics Transcription Factors
PRESS RELEASE published on 06/04/2024 at 23:07, 2 years 4 months ago QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments QUANTRO Therapeutics achieves key milestone in collaboration with Boehringer Ingelheim for first-in-class cancer treatments using proprietary technology Cancer Treatments Boehringer Ingelheim QUANTRO Therapeutics Transcription Factors R&D Program
PRESS RELEASE published on 04/04/2023 at 09:30, 3 years 6 months ago QUANTRO Therapeutics appoints Industry Expert Dr. Michael Bauer as Chief Executive Officer
Published on 11/03/2026 at 15:30, 1 hour 17 minutes ago Murchison Minerals Announces $1 Million Non-Brokered Private Placement
Published on 11/03/2026 at 15:05, 1 hour 42 minutes ago ACCESS Newswire to Host Third Quarter Earnings Conference Call on November 10, 2026
Published on 11/03/2026 at 14:31, 2 hours 16 minutes ago First Breach Adds Inspection Equipment and Secures Strategic Supply Agreements to Support Ammunition Production
Published on 11/03/2026 at 14:00, 2 hours 47 minutes ago Global Education Communities Corp. Provides Corporate Update on Student Housing Portfolio and Development Projects
Published on 11/03/2026 at 13:48, 2 hours 59 minutes ago EonX Announces Strategic Technology Partnership with Metcash, Australia's Leading Wholesaler and Service Provider to Independent Business Operators
Published on 11/03/2026 at 16:30, 16 minutes ago Shudao Investment Group Shines at the Global Panda Partners Conference 2026
Published on 11/03/2026 at 16:05, 41 minutes ago EQS-Adhoc: First Sensor AG: Change on the Supervisory Board
Published on 11/03/2026 at 16:00, 47 minutes ago hep global and Engelhart sign one of Germany’s first full Hybrid PPAs
Published on 11/03/2026 at 15:37, 1 hour 9 minutes ago Alzchem Group AG focuses on continuity in sales: Martina Spitzer’s Management Board contract extended early through 2029
Published on 11/03/2026 at 11:30, 5 hours 17 minutes ago Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Published on 11/03/2026 at 07:00, 9 hours 47 minutes ago bioMérieux – Third-Quarter 2026 Business Review
Published on 11/03/2026 at 07:00, 9 hours 47 minutes ago bioMérieux – Information financière du 3ème trimestre 2026
Published on 11/02/2026 at 21:08, 19 hours 38 minutes ago GROUPE SFPI : BILAN CONTRAT DE LIQUIDITE S1 2026
